Eylea crosses quarterly U.S. blockbuster line for Regeneron as Dupixent nears new FDA expansion
admin 6th November 2018 Uncategorised 0Regeneron’s Eylea has for the first time generated over $1 billion in quarterly U.S. sales, though the company’s overall performance looks flat in at least one analyst’s view.
More: Eylea crosses quarterly U.S. blockbuster line for Regeneron as Dupixent nears new FDA expansion
Source: fierce